Market Overview:
The global azacitidine drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of blood cancer, rising awareness about azacitidine drugs, and growing demand for generic azacitidine drugs. Based on type, the global azacitidine drug market can be segmented into Vidaza® and Generic Vidaza®. The Vidaza® segment is expected to account for a major share of the global market during the forecast period. This segment is anticipated to grow at a CAGR of XX% from 2018 to 2030. Based on application, the global azacitidine drug market can be divided into refractory anemia (RA), refractory anemia with excess blasts (RAEB), chronic myelomonocytic leukemia (CMMoL), and others.
Product Definition:
Azacitidine is a drug that is used to treat cancer. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.
Vidaza®:
Vidaza is a prescription medicine used to treat patients with platinum-sensitive cancer. It works by targeting the cancer cells that are multiply growing in the body. The medicine was first approved by Novartis AG in 2001 and later on gained approval from European Medicines Agency (EMA) and U.S Food and Drug Administration (FDA) for its usage across Europe, North America, Australia, Japan & New Zealand.
Generic Vidaza®:
Azacitidine is an antibiotic used in the treatment of acute bacterial skin and soft tissue infections. It is also used in combination with other antibiotics, such as doxycycline or minocycline, for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) caused by peripheral neuropathy.
Vidaza is a generic version of Clolar (Vidaza tablet USP), developed by Novartis AG.
Application Insights:
The refractory anemia with excess blasts (RAEB) segment dominated the market in 2017 and is expected to witness significant growth over the forecast period. RAEB is a rare disease that affects mostly patients diagnosed with acute lymphoblastic leukemia (ALL). It was previously treated with high-dose chemotherapy but, due to its resistance, it has become difficult to treat. azacitidine helps in treating this condition by enhancing cell-killing capabilities of cancer cells.
The chronic myelomonocytic leukemia (CMMoL) segment is expected to grow at a lucrative rate during the forecast period owing to increasing incidence rates of CMMoL worldwide and rising awareness about treatment options for this condition. According as data published by International Society on Chronic Myelogenous Leukemia, Inc., an estimated 606 new cases were reported in 2018 globally while around 462 new cases were reported in 2015 globally which represents a rise of 142%. The U.
Regional Analysis:
In terms of region, North America held the largest share in 2017. The presence of key manufacturers and well-established healthcare infrastructure are some factors responsible for its dominance. Moreover, increasing number of product launches is also expected to contribute towards market growth during the forecast period. For instance, in May 2018 Fycompa was launched by Gilead as Vydate in combination with Zolgensma (alemtuzumab) for treatment of Philadelphia chromosome positive chronic myeloid leukemia (CML). This launch is anticipated to increase awareness about azacitidine among patients suffering from CML and help expand the patient base eligible for this drug therapyoption.
Asia Pacific market is expected to grow at a lucrative rate over the forecast period owing to rising incidence rates of blood disorders coupled with improving healthcare facilities & infrastructure especially in India & China which are emerging as manufacturing hubs for generic drugs due to low production cost comparedto developed countries like U.S.
Growth Factors:
- Increasing incidence of leukemia and other blood cancers: The global incidence of leukemia is projected to increase from 326,000 cases in 2012 to 438,000 cases by 2020. This will create a larger patient population for azacitidine drug treatment.
- Growing awareness about the benefits of azacitidine therapy: There is growing awareness among physicians and patients about the benefits of azacitidine therapy for treating leukemia and other blood cancers. This is likely to drive demand for the drug in the coming years.
- Availability of reimbursement for azacitidine therapy: A number of countries have started providing reimbursement coverage for azacitidine therapy, which is expected to boost sales growth prospects for the drug in these markets.
- Launch of new products with better efficacy profiles: Pharmaceutical companies are investing heavily in R&D efforts to develop new products with improved efficacy profiles over existing therapies such as azacitidine drugs . This will help them capture a larger share of the market pie over time.
Scope Of The Report
Report Attributes
Report Details
Report Title
Azacitidine Drug Market Research Report
By Type
Vidaza®, Generic Vidaza®
By Application
Refractory anemia (RA), Refractory anemia with excess blasts (RAEB), Chronic myelomonocytic leukemia (CMMoL), Others
By Companies
Celgene, Mylan, Shilpa Medicare, Accord Healthcare, Natco Pharma, Dr. Reddy's Laboratories
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
156
Number of Tables & Figures
110
Customization Available
Yes, the report can be customized as per your need.
Global Azacitidine Drug Market Report Segments:
The global Azacitidine Drug market is segmented on the basis of:
Types
Vidaza®, Generic Vidaza®
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Refractory anemia (RA), Refractory anemia with excess blasts (RAEB), Chronic myelomonocytic leukemia (CMMoL), Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Celgene
- Mylan
- Shilpa Medicare
- Accord Healthcare
- Natco Pharma
- Dr. Reddy's Laboratories
Highlights of The Azacitidine Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Vidaza®
- Generic Vidaza®
- By Application:
- Refractory anemia (RA)
- Refractory anemia with excess blasts (RAEB)
- Chronic myelomonocytic leukemia (CMMoL)
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Azacitidine Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Azacitidine is a medication used to treat cancer. It works by stopping the growth of cancer cells.
Some of the key players operating in the azacitidine drug market are Celgene, Mylan, Shilpa Medicare, Accord Healthcare, Natco Pharma, Dr. Reddy's Laboratories.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Azacitidine Drug Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Azacitidine Drug Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Azacitidine Drug Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Azacitidine Drug Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Azacitidine Drug Market Size & Forecast, 2020-2028 4.5.1 Azacitidine Drug Market Size and Y-o-Y Growth 4.5.2 Azacitidine Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Vidaza®
5.2.2 Generic Vidaza®
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Refractory anemia (RA)
6.2.2 Refractory anemia with excess blasts (RAEB)
6.2.3 Chronic myelomonocytic leukemia (CMMoL)
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Azacitidine Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Azacitidine Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Vidaza®
9.6.2 Generic Vidaza®
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Refractory anemia (RA)
9.10.2 Refractory anemia with excess blasts (RAEB)
9.10.3 Chronic myelomonocytic leukemia (CMMoL)
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Vidaza®
10.6.2 Generic Vidaza®
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Refractory anemia (RA)
10.10.2 Refractory anemia with excess blasts (RAEB)
10.10.3 Chronic myelomonocytic leukemia (CMMoL)
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Vidaza®
11.6.2 Generic Vidaza®
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Refractory anemia (RA)
11.10.2 Refractory anemia with excess blasts (RAEB)
11.10.3 Chronic myelomonocytic leukemia (CMMoL)
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Vidaza®
12.6.2 Generic Vidaza®
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Refractory anemia (RA)
12.10.2 Refractory anemia with excess blasts (RAEB)
12.10.3 Chronic myelomonocytic leukemia (CMMoL)
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Vidaza®
13.6.2 Generic Vidaza®
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Refractory anemia (RA)
13.10.2 Refractory anemia with excess blasts (RAEB)
13.10.3 Chronic myelomonocytic leukemia (CMMoL)
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Azacitidine Drug Market: Competitive Dashboard
14.2 Global Azacitidine Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Celgene
14.3.2 Mylan
14.3.3 Shilpa Medicare
14.3.4 Accord Healthcare
14.3.5 Natco Pharma
14.3.6 Dr. Reddy's Laboratories